The table below shows Akebia Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$53.54M
$58.77M
$62.47M
$57.34M
$37.43M
$43.65M
Cost of revenue
$12.29M
$9.38M
$9.92M
$7.63M
$14.16M
$17.05M
Gross profit
-
-
-
-
-
-
R&D
$14.81M
$14.94M
$11.01M
$9.75M
$8.49M
$7.65M
AKBA annual revenue (10-K history)
Akebia Therapeutics, Inc. reported annual revenue of $236.20M for fiscal year 2025. That is up 47.5% from $160.18M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.53M (FY 2016) to $236.20M. Figures come from the company's audited annual reports as filed with the SEC.